Management of stable coronary artery disease

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Multivessel coronary artery disease necessitates treatment decisions between medical therapy, coronary artery bypass grafting (CABG), and percutaneous transluminal coronary angioplasty (PTCA).
• CABG demonstrates survival benefits in specific patient subsets, including left main disease or extensive disease with ischemia and left ventricular dysfunction.

Purpose of the Study:

• To compare the long-term outcomes and procedural implications of different treatment strategies for multivessel coronary artery disease.
• To inform individualized treatment approaches by analyzing the risks and benefits of medical therapy, PTCA, and CABG.

Main Methods:

• Review of existing literature and clinical guidelines comparing medical therapy, CABG, and PTCA for multivessel coronary artery disease.
• Analysis of survival rates and need for repeat revascularization procedures based on treatment modality and patient characteristics.

Main Results:

• CABG is associated with prolonged survival in patients with left main disease or extensive coronary artery disease with significant ischemia and/or left ventricular dysfunction.
• In patients with extensive coronary artery disease and normal left ventricular function, initial PTCA or CABG yield similar survival rates.
• PTCA patients experience a higher rate of repeat revascularization procedures compared to CABG patients.

Conclusions:

• Treatment selection for multivessel coronary artery disease requires a personalized strategy considering patient-specific factors, risks, and benefits.
• While PTCA offers an alternative, the higher likelihood of repeat procedures underscores the importance of careful patient selection and education.
• The complex decision-making process highlights the need for thorough patient counseling regarding medical therapy, PTCA, and CABG options.